Researchers at Massachusetts Eye and Ear/Harvard Medical School and Boston University have successfully shown neuroprotection in a Parkinson’s mouse model using new techniques to deliver drugs across the naturally impenetrable blood-brain barrier. Their findings, published in Neurosurgery, lend hope to patients around the world with neurological conditions that are difficult to treat due to a barrier mechanism that prevents approximately 98 percent of drugs from reaching the brain and central nervous system.
“We are developing a platform that may eventually be used to deliver a variety of drugs to the brain,” said senior author Benjamin S. Bleier, M.D. (in photo), of the department of otolaryngology at Mass. Eye and Ear/Harvard Medical School. “Although we are currently looking at neurodegenerative disease, there is potential for the technology to be expanded to psychiatric diseases, chronic pain, seizure disorders and many other conditions affecting the brain and nervous system down the road.”
Using nasal mucosal grafting, researchers delivered glial derived neurotrophic factor (GDNF), a therapeutic protein in testing for treating Parkinson’s disease, to the brains of mice. They showed through behavioral and histological data capture that their delivery method was equivalent to direct injection of GDNF – the current gold standard for delivering this drug in Parkinson’s disease despite its traumatic nature and high complication rates – in diffusing drugs to the brain.
The researchers chose to test their delivery method with GDNF because the therapy has been shown to delay and even reverse disease progression of Parkinson’s disease in pre-clinical models. The study was funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
“Brain diseases are notoriously difficult to treat due to the natural protections the body builds against intrusion,” said Jamie Eberling, Ph.D., senior associate director of MJFF research programs. “Dr. Bleier’s group has identified a potential avenue to pass that barrier, and we look forward to the next stage of research to further test its utility in people with Parkinson’s disease .”
Nasal mucosal grafting is a technique regularly used in the ENT field to reconstruct the barrier around the brain after surgery to the skull base. ENT surgeons commonly use endoscopic approaches to remove brain tumors through the nose by making a window through the blood-brain barrier to access the brain. Once they have finished the treatment, they use adjacent nasal lining to rebuild the hole in a permanent and safe way. The safety and efficacy of these methods have been well established through long-term clinical outcomes studies in the field, with the nasal lining protecting the brain from infection just as the blood brain barrier has done.
Dr. Bleier saw an opportunity to apply these techniques to the widespread clinical dilemma of delivering drugs across the barrier to the brain and central nervous system. By functionally replacing a section of the blood-brain barrier with nasal mucosa, which is more than 1,000 times more permeable than the native barrier, surgeons may create a “screen door” to allow for drug delivery to the brain and central nervous system.
The technique has the potential to benefit a large population of patients with neurodegenerative disorders, where there remains a specific unmet need for blood-brain penetrating therapeutic delivery strategies.
“We see this expanding beyond Parkinson’s disease, as there are multiple diseases of the brain that do not have good therapeutic options,” Dr. Bleier said. “It is a platform that opens doors for new discovery and could enable drug development for an underserved population.”
The Latest on: neurodegenerative disorders
via Google News
The Latest on: neurodegenerative disorders
- Parkinson’s Disease Symptoms Reversed by Replacing Lost Neurons in Miceon June 26, 2020 at 5:00 am
Scientists converted astrocytes to functional neurons by depleting the RNA-binding protein PTB, reversing symptoms in a mouse model of Parkinson's disease.
- Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s diseaseon June 26, 2020 at 4:40 am
Neurofilament light chain (NFL) measurement has been gaining strong support as a clinically useful neuronal injury biomarker for various neurodegenerative conditions. However, in Alzheimer’s disease ...
- Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer’s Disease Agitationon June 26, 2020 at 4:00 am
About Alzheimer’s Disease (AD) Agitation Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, and behavioral and psychological symptoms including ...
- Parkinson's disease breakthrough seen in mouse modelon June 25, 2020 at 6:37 pm
Researchers from the University of California San Diego School of Medicine have found a way to create new neurons in a mouse model of Parkinson's disease. The severely debilitating and progressive ...
- One-time treatment generates new neurons, eliminates Parkinson's disease in miceon June 25, 2020 at 12:20 pm
Researchers have discovered that a single treatment to inhibit a gene called PTB in mice converts native astrocytes, brain support cells, into neurons that produce the neurotransmitter dopamine. As a ...
- National Institute on Aging awards $15 million to Stanford’s Alzheimer’s Disease Research Centeron June 25, 2020 at 11:44 am
The Stanford-based center’s affiliated faculty and staff, aided by more than 400 volunteers, conduct research on Alzheimer’s and Parkinson’s diseases and related disorders.
- New therapeutic approach for Parkinson’s and other neurodegenerative diseaseson June 24, 2020 at 10:19 pm
Dong Fu, PhD, has never been more excited about something in his entire career. He has long studied the basic biology of RNA, a genetic cousin of DNA, and the proteins that bind it. But a single ...
- Inflammatory bowel disease linked to doubling in dementia riskon June 24, 2020 at 7:09 pm
Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is linked to a more than doubling in the risk of developing dementia, finds new research.
- Orphazyme phase 2 study of arimoclomol in Gaucher disease demonstrates marked improvements in key clinical markerson June 24, 2020 at 9:30 am
Orphazyme A/SCompany announcement No. 36/2020.
- Reversing a model of Parkinson’s disease with in situ converted nigral neuronson June 24, 2020 at 8:15 am
Depletion of the RNA-binding protein PTB (also known as PTBP1) in astrocytes reprograms these cells to become functional neurons and, in a mouse model of Parkinson’s disease, reverses the disease ...
via Bing News